
IRIDEX Corporation
IRIXNASDAQHealthcareMedical - Devices
前收盘价
US$0.7561
−US$0.0055 · -0.72%
盘前
US$0.7405
−US$0.0156 · -2.06%
8月24日 4:02 ET
IRIX公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Hold
Wait — insufficient conviction to act
估值
67
Undervalued
动量
48
Neutral
情绪
53
Mixed
风险韧性
46
Elevated Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
- 行业
- Medical - Devices
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Patrick Mercer
- 上市以来
- 1996年2月16日
- 雇员
- 93
市场位置
日内区间
当前US$0.7561,
52周区间
当前US$0.7561,
- 开盘价
- US$0.7528
- 前收盘价
- US$0.7616
- 成交量
- 14.62万
- 2.2× 平均值
- 平均成交量
- 6.64万
- 日均成交量
- 市值
- 1308.61万 USD
- 贝塔
- 0.64
- 市场参考 1
- 50天平均值
- US$0.9884
- 低于平均水平-23.50%
- 200天平均值
- US$1.1201
- 低于平均水平-32.50%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 1861.28万 USD
- 市盈率(TTM)
- -3.72×
- 市净率(TTM)
- 3.61×
- 市销率(TTM)
- 0.25×
- EV/EBITDA
- -6.57×
- 盈利收益率
- -22.06%
- 自由现金流收益率
- -11.23%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 36.23%
- 营业利润率
- -5.39%
- 净利润率
- -6.88%
- 净资产收益率
- -90.15%
- 资产收益率
- -15.22%
- 投入资本回报率
- -15.45%
财务健康
- 负债权益比
- 1.1×
- 流动比率
- 1.91×
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5267.5万 USD | 4866.9万 USD | 5186.9万 USD | 5697.2万 USD | 5390.3万 USD |
| 销货成本 | 3336.9万 USD | 2916.7万 USD | 3006.2万 USD | 3160.4万 USD | 3107.2万 USD |
| 毛利 | 1930.6万 USD | 1950.2万 USD | 2180.7万 USD | 2536.8万 USD | 2283.1万 USD |
| 研究与开发 | 366.8万 USD | 544.9万 USD | 682.9万 USD | 717.5万 USD | 686.8万 USD |
| 销售、一般及管理费用 | 1813万 USD | 2235.5万 USD | 2498.5万 USD | 2573.5万 USD | 2349.6万 USD |
| 营业费用 | 2187.7万 USD | 2780.4万 USD | 3181.4万 USD | 3291万 USD | 3036.4万 USD |
| 折旧和摊销 | 154.7万 USD | 142.4万 USD | 203.2万 USD | 138.4万 USD | 80.3万 USD |
| 营业利润 | −257.1万 USD | −830.2万 USD | −1000.7万 USD | −754.2万 USD | −753.3万 USD |
| 净利润 | −443.7万 USD | −891万 USD | −957万 USD | −754.7万 USD | −522.5万 USD |
公司数据更新于 2026年8月24日。
财报历史与展望
- EPS超预期率
- 27%
- 超预期3次、低于预期6次、符合预期2次
- 平均EPS意外幅度
- -110.11%
- 11 类似报告
- 最新每股收益结果
- -0.07
- 预期-0.01 · 低于预期600.00%
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
分析师评级
第三方分析师预期可能变化,并非 GoAI 建议。
分析师目标价
平均目标
US$2.75
上涨空间 263.71%价格历史记录不可用
最高:US$2.75平均的:US$2.75最低:US$2.75IRIX 消息
IRIX同业公司
持有IRIX的ETF
报告持有此股票敞口的交易所交易基金。
继续GoAI的研究
在 GoAI 中研究IRIXresearch.disclaimer













